MedTrace Logo

Screening Protocol for the Evaluation of Research Participants

NCT01036217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55000

Last updated 2017-07-02

No results posted yet for this study

Summary

Background:

\- The National Institute on Drug Abuse (NIDA) uses a standardized set of procedures to develop a pool of potential participants for research studies. Because some of the data collected during screening are used later for research, the screening itself is considered a study. An applicant to any NIDA study is considered a participant in NIDA screening.

Objectives:

\- To identify, recruit, and screen participants for NIDA research protocols.

Eligibility:

\- Individuals 18 years of age and older who are able to provide informed consent.

Design:

* Individuals who are eligible for screening will undergo two interviews: a telephone interview and an in-person interview. The phone interview will determine eligibility for the in-person interview.
* The in-person interview may require up to five visits to NIDA. The in-person visit will involve any or all of the following procedures: (1) full physical examination and medical history; (2) psychiatric interview; (3) psychological testing; (4) electrocardiogram; (5) samples of blood, urine, and hair; and (6) other minimally invasive procedures as directed by the research staff.
* During screening, a photograph will be taken for confirmation of identity during subsequent visits for other studies.
* No clinical care will be provided as part of screening.

Conditions

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-17
Completion
2010-06-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01036217 on ClinicalTrials.gov